CXCL10 and head and neck squamous cell carcinoma: In our experiments, the combination of both antibodies increased the IP-10 concentrations in some HNSCC samples that did not respond to pembrolizumab with IP-10 release, suggesting a compensation of the anti-IP-10 effects of pembrolizumab in these HNSCC samples.